Make notes on topical steroid damaged facies for md dermatology theory exam

Reading File
Finding Sources
Finding Sources
Searching Images

topical steroid damaged facies erythema telangiectasia perioral

Searching PubMed

"topical steroid damaged face"

Searching the Web

topical steroid damaged facies TSDF clinical features management review

Reading File
Reading Web Page

https://pmc.ncbi.nlm.nih.gov/articles/PMC4885178

Searching Images

steroid rosacea perioral dermatitis face telangiectasia

This is a frontal clinical photograph of an adult patient’s face illustrating steroid-induced facial rosacea with perioral dermatitis. Modality: Digital color photography, in vivo, captured under standard indoor lighting with routine color balance. Anatomical region: central face including cheeks, nasal area, perioral region and adjacent perinasal skin. The image shows diffuse erythema with a prominent papulopustular eruption, fine scaling, and subtle telangiectasia across the malar cheeks and nasal bridge, extending around the mouth. Bilateral distribution is evident, with accentuation along the nasolabial folds and perioral zone. Palpebral and eyelid skin not clearly involved. The lesions are small to moderate in size, with confluent erythematous patches interspersed by discrete papules and pustules; surface texture appears tender and mildly edematous. Clinically, the appearance is characteristic of corticosteroid-related facial dermatitis, specifically steroid-induced rosacea and perioral dermatitis, often resulting from recent or prolonged topical corticosteroid use. Diagnostic significance: history of steroid exposure with paradoxical facial inflammation; differential includes rosacea not steroid-related, acneiform dermatitis, seborrheic dermatitis, and contact dermatitis. Clinical correlation: cessation of potent steroids, gradual taper, and initiation of appropriate dermatologic therapy typically yield gradual improvement over weeks to months. Potential clinical use: education, documentation, disease monitoring, AI-training datasets for dermatology.

This is a frontal clinical photograph of an adult patient’s face illustrating steroid-induced facial rosacea with perioral dermatitis. Modality: Digital color photography, in vivo, captured under standard indoor lighting with routine color balance. Anatomical region: central face including cheeks, nasal area, perioral region and adjacent perinasal skin. The image shows diffuse erythema with a prominent papulopustular eruption, fine scaling, and subtle telangiectasia across the malar cheeks and nasal bridge, extending around the mouth. Bilateral distribution is evident, with accentuation along the nasolabial folds and perioral zone. Palpebral and eyelid skin not clearly involved. The lesions are small to moderate in size, with confluent erythematous patches interspersed by discrete papules and pustules; surface texture appears tender and mildly edematous. Clinically, the appearance is characteristic of corticosteroid-related facial dermatitis, specifically steroid-induced rosacea and perioral dermatitis, often resulting from recent or prolonged topical corticosteroid use. Diagnostic significance: history of steroid exposure with paradoxical facial inflammation; differential includes rosacea not steroid-related, acneiform dermatitis, seborrheic dermatitis, and contact dermatitis. Clinical correlation: cessation of potent steroids, gradual taper, and initiation of appropriate dermatologic therapy typically yield gradual improvement over weeks to months. Potential clinical use: education, documentation, disease monitoring, AI-training datasets for dermatology.

Clinical photograph of a middle-aged adult male presenting with facial steroid-induced rosacea and postinflammatory hyperpigmentation. Modality: Clinical photography; frontal view of the face under diffuse, non-diagnostic lighting. The centrofacial skin shows diffuse erythema with prominent telangiectasia, especially on the cheeks and nose. Superimposed papules and few pustules are evident around the nasolabial folds and forehead, with patchy hyperpigmented macules on the malar regions. The perioral area may be involved, and there is mild edema and skin fragility consistent with steroid-related epidermal thinning. Bilateral distribution is noted, with involvement of forehead, cheeks, and perioral skin. This pattern is characteristic of topical corticosteroid overuse leading to an inflammatory rosaceiform eruption rather than classic acne. The clinical diagnosis is steroid-induced rosacea with pigmentary changes; histopathology is not provided. Diagnostic significance includes recognizing steroid-related dermatosis to prevent progression and guide withdrawal and treatment. Differential diagnoses include rosacea (non-steroid–associated), acne vulgaris, perioral dermatitis, and dermatitis from irritants. Clinical correlation should focus on patient history of potent facial steroid use, duration, and taper strategy. This image is educational for dermatology training, medical education, and AI-assisted lesion recognition, highlighting pigmentary complications and telangiectasia in centrofacial dermatoses. Clinically, cessation of potent steroids is essential.

Clinical photograph of a middle-aged adult male presenting with facial steroid-induced rosacea and postinflammatory hyperpigmentation. Modality: Clinical photography; frontal view of the face under diffuse, non-diagnostic lighting. The centrofacial skin shows diffuse erythema with prominent telangiectasia, especially on the cheeks and nose. Superimposed papules and few pustules are evident around the nasolabial folds and forehead, with patchy hyperpigmented macules on the malar regions. The perioral area may be involved, and there is mild edema and skin fragility consistent with steroid-related epidermal thinning. Bilateral distribution is noted, with involvement of forehead, cheeks, and perioral skin. This pattern is characteristic of topical corticosteroid overuse leading to an inflammatory rosaceiform eruption rather than classic acne. The clinical diagnosis is steroid-induced rosacea with pigmentary changes; histopathology is not provided. Diagnostic significance includes recognizing steroid-related dermatosis to prevent progression and guide withdrawal and treatment. Differential diagnoses include rosacea (non-steroid–associated), acne vulgaris, perioral dermatitis, and dermatitis from irritants. Clinical correlation should focus on patient history of potent facial steroid use, duration, and taper strategy. This image is educational for dermatology training, medical education, and AI-assisted lesion recognition, highlighting pigmentary complications and telangiectasia in centrofacial dermatoses. Clinically, cessation of potent steroids is essential.

Clinical dermatology photograph of the face, frontal view, documenting steroid-induced rosacea involving the malar (cheek) and chin regions. Modality: clinical digital photography; technique: standardized facial lighting, color-balanced imaging; specimen: human skin; view: anterior facial aspect. Anatomical context: integumentary system; facial skin on the central face, cheeks (malar regions) and chin, bilateral distribution, anterior plane. Visual features: diffuse erythema with fine papules and minimal pustulation, subtle perifollicular accentuation, and mild visible telangiectasia in the affected zones; skin texture appears slightly roughened with reactive hyperemia; absence of comedones or nodular infiltration in this frame. Diagnostic implication: fits steroid-induced rosacea spectrum rather than classic acne vulgaris; triggers include potent topical corticosteroids; history of recent steroid use would corroborate; differential diagnoses include acne rosacea, steroid dermatitis, perioral dermatitis, contact dermatitis. Clinical significance: highlights adverse cutaneous effect of topical steroids, guides management (withdrawal or taper, barrier repair, anti-inflammatory strategies, calcineurin inhibitors, non-irritant skincare, photoprotection). Potential clinical use cases: educational reference for dermatology training, case-based learning on iatrogenic rosacea, monitoring response to withdrawal therapy, decision support for treatment planning, and aiding patient counseling about steroid safety and rosacea flares. This image supports standardized documentation, teaching symptom recognition, and guiding patient-tailored stop-start therapy.

Clinical dermatology photograph of the face, frontal view, documenting steroid-induced rosacea involving the malar (cheek) and chin regions. Modality: clinical digital photography; technique: standardized facial lighting, color-balanced imaging; specimen: human skin; view: anterior facial aspect. Anatomical context: integumentary system; facial skin on the central face, cheeks (malar regions) and chin, bilateral distribution, anterior plane. Visual features: diffuse erythema with fine papules and minimal pustulation, subtle perifollicular accentuation, and mild visible telangiectasia in the affected zones; skin texture appears slightly roughened with reactive hyperemia; absence of comedones or nodular infiltration in this frame. Diagnostic implication: fits steroid-induced rosacea spectrum rather than classic acne vulgaris; triggers include potent topical corticosteroids; history of recent steroid use would corroborate; differential diagnoses include acne rosacea, steroid dermatitis, perioral dermatitis, contact dermatitis. Clinical significance: highlights adverse cutaneous effect of topical steroids, guides management (withdrawal or taper, barrier repair, anti-inflammatory strategies, calcineurin inhibitors, non-irritant skincare, photoprotection). Potential clinical use cases: educational reference for dermatology training, case-based learning on iatrogenic rosacea, monitoring response to withdrawal therapy, decision support for treatment planning, and aiding patient counseling about steroid safety and rosacea flares. This image supports standardized documentation, teaching symptom recognition, and guiding patient-tailored stop-start therapy.

Clinical photography of an adult's face showing a diffuse erythematous papulopustular eruption consistent with steroid-induced rosacea. Modality: Clinical photography; anterior facial view. The cheeks, nasal bridge, perioral regions are symmetrically involved with diffuse erythema and scattered inflamed papules and pustules; mild edema and telangiectasia may be present but not clearly visible. Anatomical regions include the malar and nasolabial areas. The eruption reflects inflammatory infiltration of the epidermis and superficial dermis with vascular dilation. Pathophysiology likely relates to prolonged topical corticosteroid suppression of innate immunity and induction of vasodilation leading to rosacea-like eruption; withdrawal and gradual tapering of steroids are essential. Differential diagnoses include acne rosacea, acne vulgaris, perioral dermatitis, seborrheic dermatitis, and contact dermatitis. Diagnostic significance: steroid-induced facial rosacea is typically reversible with appropriate management after identifying and stopping the offending agent, though lingering erythema may persist. Clinical use cases include educational demonstration, differential diagnosis training, and guiding management decisions. The image supports recognition of steroid-induced rosacea patterns, informs patient counseling on prognosis, and assists in planning skin barrier restoration and anti-inflammatory therapy. High-quality color fidelity and standard lighting enhance lesion visualization for teaching and remote consultation. This description emphasizes morphological details such as papules, pustules, and diffuse erythema present.

Clinical photography of an adult's face showing a diffuse erythematous papulopustular eruption consistent with steroid-induced rosacea. Modality: Clinical photography; anterior facial view. The cheeks, nasal bridge, perioral regions are symmetrically involved with diffuse erythema and scattered inflamed papules and pustules; mild edema and telangiectasia may be present but not clearly visible. Anatomical regions include the malar and nasolabial areas. The eruption reflects inflammatory infiltration of the epidermis and superficial dermis with vascular dilation. Pathophysiology likely relates to prolonged topical corticosteroid suppression of innate immunity and induction of vasodilation leading to rosacea-like eruption; withdrawal and gradual tapering of steroids are essential. Differential diagnoses include acne rosacea, acne vulgaris, perioral dermatitis, seborrheic dermatitis, and contact dermatitis. Diagnostic significance: steroid-induced facial rosacea is typically reversible with appropriate management after identifying and stopping the offending agent, though lingering erythema may persist. Clinical use cases include educational demonstration, differential diagnosis training, and guiding management decisions. The image supports recognition of steroid-induced rosacea patterns, informs patient counseling on prognosis, and assists in planning skin barrier restoration and anti-inflammatory therapy. High-quality color fidelity and standard lighting enhance lesion visualization for teaching and remote consultation. This description emphasizes morphological details such as papules, pustules, and diffuse erythema present.

Modality and technique: high-resolution clinical photography of the face in frontal/anterior view, providing a close-up assessment of cutaneous inflammation. Anatomical focus: central facial skin encompassing the nasal dorsum, cheeks, nasolabial folds, and perioral region. Observed features: uniform facial erythema with prominent edema, particularly on the malar cheeks and nasal pyramid, accompanied by discrete papules and pustules within inflamed erythematous areas. The texture appears smooth to slightly glossy, with diffuse vascular blush and minor swelling around the nose and midface. The pattern is bilateral and symmetrical, consistent with steroid-induced rosacea (SR), a dermatosis precipitated by topical or systemic corticosteroid exposure. Differential considerations include acne rosacea, perioral dermatitis, dermatitis medicamentosa, and contact dermatitis; however, the history of steroid use and the central facial predominance favor SR. Pathophysiology involves disruption of pilosebaceous unit homeostasis and steroid-induced telangiectasia, leading to papulopustular flares. Clinical significance lies in the need to discontinue the offending steroid, initiate rosacea-appropriate therapy (e.g., metronidazole, doxycycline, brimonidine), and monitor for rebound flaring. Potential clinical uses include documenting treatment response, educating patients, and supporting differential diagnosis in photodermatology and cosmetic dermatology. This image exemplifies central facial inflammation with papulopustular lesions in SR. Interpretation aids patient counseling and targeted management planning for clinicians.

Modality and technique: high-resolution clinical photography of the face in frontal/anterior view, providing a close-up assessment of cutaneous inflammation. Anatomical focus: central facial skin encompassing the nasal dorsum, cheeks, nasolabial folds, and perioral region. Observed features: uniform facial erythema with prominent edema, particularly on the malar cheeks and nasal pyramid, accompanied by discrete papules and pustules within inflamed erythematous areas. The texture appears smooth to slightly glossy, with diffuse vascular blush and minor swelling around the nose and midface. The pattern is bilateral and symmetrical, consistent with steroid-induced rosacea (SR), a dermatosis precipitated by topical or systemic corticosteroid exposure. Differential considerations include acne rosacea, perioral dermatitis, dermatitis medicamentosa, and contact dermatitis; however, the history of steroid use and the central facial predominance favor SR. Pathophysiology involves disruption of pilosebaceous unit homeostasis and steroid-induced telangiectasia, leading to papulopustular flares. Clinical significance lies in the need to discontinue the offending steroid, initiate rosacea-appropriate therapy (e.g., metronidazole, doxycycline, brimonidine), and monitor for rebound flaring. Potential clinical uses include documenting treatment response, educating patients, and supporting differential diagnosis in photodermatology and cosmetic dermatology. This image exemplifies central facial inflammation with papulopustular lesions in SR. Interpretation aids patient counseling and targeted management planning for clinicians.

Reading File

Topical Steroid Damaged Facies (TSDF) — MD Dermatology Exam Notes

1. Definition

Topical Steroid Damaged/Dependent Face (TSDF) is a clinical entity characterized by a constellation of facial cutaneous adverse effects resulting from unsupervised, prolonged, or inappropriate misuse/abuse of topical corticosteroids (TC) of any potency on the face, leading to a state of cutaneous steroid dependence with rebound flare on withdrawal (Lahiri & Coondoo, Indian J Dermatol 2016, PMID: 27293246).
  • Older synonym: "Red Face Syndrome" (Rapaport, 1999) — erythema is considered the hallmark feature.
  • Also described as an entity of cutaneous pharmacodependence — analogous to drug addiction, with psychological compulsion to keep applying steroid despite awareness of harm.
  • Coined/popularized in India (Lahiri, 2008) due to an epidemic of OTC misuse; led to a pan-Indian IADVL multicentric study (2008-2009).

2. Epidemiology & Precipitating Factors

  • Extremely common in India/South Asia due to over-the-counter (OTC) availability of potent/super-potent steroids without prescription.
  • Fixed-dose combination creams widely misused: potent steroid (e.g., clobetasol propionate) + antifungal + antibacterial + tretinoin — marketed and self-used as "fairness creams" or for minor complaints (acne, melasma, insect bites, "pimples," tanning).
  • Driven by quackery, cosmetic counter sales, peer/advertisement influence, and desire for fairness/glow.
  • Facial skin is uniquely vulnerable: thinner stratum corneum, higher density of pilosebaceous units and blood vessels, greater percutaneous absorption than trunk/limb skin — hence lower threshold for steroid-induced damage.

3. Pathogenesis

  • Chronic vasoconstriction from TC followed by rebound vasodilatation on stoppage -> persistent erythema and telangiectasia.
  • Antimitotic/antiproliferative effect -> epidermal and dermal atrophy, decreased collagen/elastin synthesis -> thin, fragile, translucent skin with visible vessels.
  • Local immunosuppression -> proliferation of Demodex folliculorum, subclinical dermatophyte infection (tinea incognito), and bacterial folliculitis.
  • Comedogenic and follicular occlusive effect -> steroid acne/secondary comedones.
  • Nitric oxide-mediated vascular dysregulation contributes to the rosacea-like papulopustular component (steroid rosacea).

4. Clinical Features

Erythema is the hallmark — diffuse, persistent, burning/stinging facial redness. Associated features:
CategoryFeatures
VascularDiffuse erythema, telangiectasia, flushing, papulopustular rosacea-like eruption
AtrophicEpidermal/dermal atrophy, thinning, striae (especially periorbital), easy bruising, shiny skin
FollicularSteroid acne, secondary comedones, perioral dermatitis, folliculitis
PigmentaryMottled hyper- and hypopigmentation
InfectiveTinea incognito, demodicosis, bacterial superinfection
SensoryBurning, stinging, tightness, photosensitivity
AdnexalHypertrichosis (steroid-induced facial hirsutism, especially cheeks/forehead)
Rebound/withdrawalSevere flare of erythema/burning on stopping steroid — drives dependence; may spread beyond original application site
Systemic (rare, with prolonged widespread potent use)HPA-axis suppression, cushingoid features; periocular use risk of glaucoma/cataract (warrants ophthalmology referral)
Fitzpatrick's Dermatology describes the overlapping entity "Steroid Rosacea": complexion turns deep flaming or copper-red with a network of telangiectasias; atrophic skin develops scaling, follicular papulopustules, nodules, and secondary comedones, typically restricted to the site of corticosteroid application, with severe discomfort/pain (Fitzpatrick's Dermatology, Vol 1-2, p. Ch. 79).
Steroid-induced facial rosacea with perioral dermatitis
Steroid rosacea with telangiectasia and pigmentary change

5. Dermoscopy (high-yield for MD exam)

Reference: Sonthalia et al., Dermatol Pract Concept 2018 (PMID: 30116656); Jakhar & Kaur, Indian Dermatol Online J 2018 (PMID: 30050829).
  • Diffuse polygonal/linear branching (arborizing) vessels on a milky-red to pink-red background
  • Follicular red dots and prominent follicular openings
  • Perifollicular whitish halo
  • Fine scaling; comedo-like structures in acneiform variant
  • Dermoscopy is useful to differentiate TSDF from primary rosacea, seborrheic dermatitis, and connective tissue disease, and to objectively monitor response during steroid tapering.

6. Grading

Clinical severity commonly graded as mild / moderate / severe based on extent of erythema, presence and density of papulopustules, degree of atrophy/telangiectasia, and impact on quality of life (used in Indian multicentric TSDF studies, e.g., Pal et al., Indian J Dermatol 2018, PMID: 30210157; Sharma et al., Cureus 2024, PMID: 39803119).

7. Differential Diagnosis

  • Primary rosacea (papulopustular/erythematotelangiectatic)
  • Perioral dermatitis (non-steroid)
  • Seborrheic dermatitis
  • Photodermatitis / chronic actinic dermatitis
  • Connective tissue disease (lupus malar rash)
  • Contact dermatitis / status cosmeticus
  • Tinea incognito (isolated)
Key differentiator: history of prolonged/unsupervised topical steroid use on the face + rebound flare on stopping clinches TSDF.

8. Management

  1. Patient counseling and education — central to management given the psychological/behavioral dependence component; explain the rebound phenomenon in advance so patient does not restart steroid out of panic.
  2. Never abrupt stop of potent steroid — taper gradually:
    • Step down potency (e.g., potent -> mild) and/or
    • Reduce frequency (daily -> alternate day -> twice weekly -> stop) over weeks.
  3. Steroid-sparing bridge therapy: topical calcineurin inhibitors (tacrolimus 0.03-0.1%, pimecrolimus 1%) to control inflammation during taper without further atrophy.
  4. Barrier repair: bland emollients/ceramide-based moisturizers for xerosis and skin fragility.
  5. Photoprotection: broad-spectrum, preferably mineral/physical sunscreens (photosensitized skin).
  6. Treat secondary complications:
    • Papulopustular/rosacea-like component: oral doxycycline/tetracycline, topical metronidazole or azelaic acid
    • Demodicosis: topical permethrin/ivermectin
    • Tinea incognito: appropriate oral/topical antifungal (avoid combination creams)
    • Secondary bacterial infection: targeted antibiotics
  7. Cool compresses, avoidance of irritant cosmetics/cleansers during acute rebound phase.
  8. Psychiatric/psychological referral in cases with marked dependence behavior or comorbid anxiety/OCD traits.
  9. Systemic evaluation if extensive potent steroid use over prolonged period is suspected — morning cortisol/ACTH stimulation test for HPA-axis suppression; ophthalmology referral if periocular application.
  10. Public health/regulatory angle (favorite exam point): IADVL's advocacy led to India restricting OTC sale of potent topical corticosteroid combinations under Schedule H — highlights the socio-regulatory dimension of TSDF.

9. Prognosis

Largely reversible with structured withdrawal and supportive therapy, though erythema/telangiectasia may take weeks to months to settle, and some vascular change can be persistent, occasionally requiring vascular laser (pulsed dye laser) for residual telangiectasia.

Exam-Focused High-Yield Points

  • Erythema = hallmark sign; rebound phenomenon = defining feature of "dependence."
  • Term coined by Lahiri and Coondoo (2008), India.
  • Driven by OTC potent steroid + antifungal + antibacterial combination creams.
  • Dermoscopy: polygonal/arborizing vessels + follicular red dots + perifollicular whitish halo.
  • Management principle: taper, never abrupt stop; use TCI as bridge; counsel for dependence behavior.

Recent literature check (for currency)

A recent dermoscopic analysis (Meghe et al., J Pharm Bioallied Sci 2024, PMID: 38882848) and a tertiary-care descriptive study from Northern India (Sharma et al., Cureus 2024, PMID: 39803119) reaffirm the same clinical/dermoscopic picture described above — no major contradiction to the classical teaching found. No new systematic review/meta-analysis on TSDF was identified in the last 2 years; the evidence base remains largely observational/cross-sectional Indian case series, which is itself worth mentioning as a limitation if asked about "evidence quality" in the exam.
Key references: Lahiri & Coondoo, Indian J Dermatol 2016 (PMID: 27293246); Pal et al., Indian J Dermatol 2018 (PMID: 30210157); Sonthalia et al., Dermatol Pract Concept 2018 (PMID: 30116656); Jakhar & Kaur, Indian Dermatol Online J 2018 (PMID: 30050829); Fitzpatrick's Dermatology, Vol 1-2, Chapter 79 (Steroid Rosacea).
This is a shared conversation. Sign in to Orris to start your own chat.